Sacituzumab Govitecan Provides More Treatment Options in HER2– Breast Cancer

Video

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

The FDA’s previous approval of sacituzumab govitecan-hziy (Trodelvy) has opened up new treatment options outside of standard chemotherapy for patients with hormone receptor (HR)–positive or HER2-negative or -low metastatic breast cancer who are endocrine therapy refractory, according to Sara M. Tolaney, MD, MPH.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, about how findings from the phase 3 TROPiCS-02 study’s (NCT03901339) final overall survival analysis further support the benefit of sacituzumab govitecan in this population following the FDA’s approval of the agent in February 2023.1,2

Data from the analysis highlighted that sacituzumab govitecan improved overall survival in the HER2 IHC0 (Hazard ratio [HR], 0.85; 95% CI, 0.63-1.14) and HER2-low populations vs single agent chemotherapy (HR, 0.75; 95% CI, 0.57-0.97).

Transcript:

It's really exciting to have more treatment options for patients with pretreated metastatic [HR]-positive disease. The data from TROPiCS-02 certainly reinforces that sacituzumab govitecan does have benefit for this population, not just in terms of progression-free survival, but also in terms of a clinically meaningful and significant improvement in survival. It has opened up treatment options.

Many patients who are HER2-low will start off with a line of standard chemotherapy, go on to get [trastuzumab deruxtecan; Enhertu], and then subsequently go on to get sacituzumab. For those patients who are not HER2-low, [who] have a HER2 IHC of 0, and [estrogen receptor]–positive [disease], then we're often turning to sacituzumab even earlier. [Patients] will often get a line of chemotherapy and then go to sacituzumab. [The approval of sacituzumab] is allowing for more choices outside of just standard chemotherapy once people become endocrine refractory, which is great for patients.

References

  1. U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed June 5, 2023. https://bwnews.pr/3Y0bftX
  2. Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.